Skip to content
Biotechnology

Cambridge Isotope Laboratories Launches ISOLED-D: Revolutionary Deuterated Reagents for OLED Manufacturing

Cambridge Isotope Laboratories, Inc. 2 mins read

New ISOLED-D™ line delivers premium, scalable deuterated reagents for OLED synthesis, supporting the industry from R&D through commercial production with CIL's global manufacturing and expertise.

TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / May 20, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), the global leader in stable isotope-labeled products, announces the launch of ISOLED-D™, a groundbreaking line of deuterated reagents specifically designed for organic light-emitting diode (OLED) synthesis.

ISOLED-D LOGO
ISOLED-D LOGO
ISOLED-D - deuterated reagents specifically designed for organic light-emitting diode

ISOLED-D represents a significant advancement in OLED manufacturing technology, offering high-quality deuterated reagents with manufacturing in state-of-the-art, strategically located worldwide facilities. The product line caters to various production scales, from gram quantities for research and development to metric-ton volumes for full-scale commercial manufacturing.

"ISOLED-D demonstrates our commitment to advancing OLED technology through innovative isotope-labeled solutions," said Tasha Agreste, Business Development Manager for Deuterated Reagents at CIL. "Our ability to scale production from laboratory to industrial quantities positions us as a crucial partner in the OLED manufacturing ecosystem."

The company's flexible approach enables seamless collaboration with research and development teams through to commercial production, ensuring consistent quality and reliable supply chains for manufacturers in the rapidly growing OLED market.

Key features of ISOLED-D:

  • Premium-grade deuterated reagents for OLED synthesis

  • Scalable production capabilities from grams to metric tons

  • Manufacturing in state-of-the-art facilities

  • Complete R&D to commercialization support

  • Backed by CIL's industry-leading expertise in stable isotope-labeled products

  • Deuterated Benzene Recovery program

For more information about ISOLED-D and CIL's complete range of isotope-labeled products, visit isotope.com.

Contact Information

Crissy Krisko
[email protected]
1.978.269.1930

.

SOURCE: Cambridge Isotope Laboratories, Inc.



View the original press release on ACCESS Newswire

More from this category

  • Biotechnology
  • 12/06/2025
  • 11:26
CLEO DIAGNOSTICS LTD

Corporate Presentation June 2025

Cleo Diagnostics shares its updated June 2025 corporate presentation outlining the Company’s strategy and progress on “Pioneering the Transformation of Ovarian Cancer Detection.” The…

  • Contains:
  • Biotechnology, Environment
  • 05/06/2025
  • 12:13
EcoPHA

Australia’s New Green Alliance: How Pongamia Trees and PHA Are Powering a Cleaner Future

June 2025 – Australia As global industry races to decarbonise, an unlikely hero is emerging from the Australian landscape: the pongamia tree. Recently highlighted in Rio Tinto’s ambitious biofuels project, this native species is now at the centre of a broader movement, one that includes sustainable bioplastics, climate-resilient agriculture, and nature-based solutions to emissions reduction. Australia's very own leading biotech firm, EcoPHAis proud to announce its integrated pongamia plantation and bioplastic initiative - linking reforestation,biofuel, and bioplastic innovation into a single circular economy model. While Rio Tinto’s planting of 750,000 pongamia trees near Townsville marks a bold step toward renewable…

  • Biotechnology, Medical Health Aged Care
  • 02/06/2025
  • 11:54
INOVIQ Limited

EARLY OVARIAN CANCER SCREENING BREAKTHROUGH

INOVIQ Limited (ASX: IIQ) is pleased to announce game-changing results from its EXO-OC™ ovarian cancer test presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on 1 June 2025 in Chicago. The Poster titled Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test is copied below. The test uses proprietary technology to isolate exosomes and combines multiple exosomal biomarkers in an AI-enhanced algorithm to enable the early and accurate detection of ovarian cancer. Since reporting high level results from a biomarker study validating protein biomarkers on 3 December 2024, INOVIQ worked with one of Australia’s most…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.